3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
17
Neoplasms
6
Pancreatic Neoplasms
5
Lung Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Head and Neck Neoplasms
3
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Rhabdoid Tumor
1
Respiratory Tract Diseases
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Intraductal Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Interventions
Magnetic Resonance Spectroscopy
11
trametinib
8
selpercatinib
7
pembrolizumab
7
dabrafenib
7
Nivolumab
7
Iodine-131
6
lenvatinib
5
Specimen Handling
5
Biopsy
5
cabozantinib
4
Vemurafenib
4
Iodine-124
4
larotrectinib
3
durvalumab
3
binimetinib
3
anlotinib
3
Ipilimumab
3
Immunoglobulin G
3
Fluorodeoxyglucose F18
3
Disulfides
3
Cyclophosphamide
3
Cetuximab
3
vandetanib
2
ulixertinib
2
pralsetinib
2
omipalisib
2
defactinib
2
copanlisib
2
cemiplimab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
Erlotinib Hydrochloride
×
1 year
×
Clear all
No trials found.